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Factor V marks platelet-
primed megakaryocytes
-----------------------------------------------------------------------------------------------------
Alessandra Bertoni UNIVERSITY OF PIEMONTE ORIENTALE
In this issue of Blood, Sim et al identify novel distinct human megakaryocyte
populations primed for platelet release and establish a new approach to isolate
such populations to generate either in vitro or in vivo functional human platelets.1
P latelets are circulating anucleate cellsthat play a central role in hemostasis,
thrombosis, and inflammation. Platelets are the
final products of a complex maturation process
that involves the differentiation of multipotent
hematopoietic stem cells in mature
megakaryocytes. This maturation process is
characterized by increase in cell size, ploidy,
granular components, megakaryocyte-specific
surface receptors, and the formation of an
invaginated membrane system.2
Platelet transfusions are commonly used
clinically to treat or prevent hemorrhage in
people with either thrombocytopenia or
platelet function defects. Platelet transfusions
are employed extensively and increasingly,
although they have some associated risks, such
as allergic reactions and bacterial and viral
infections.3 At present, the only source of
platelets for transfusion is donation from
volunteers.
One of the main difficulties associated
with platelet transfusions is the availability
of adequate hospital platelet inventories. To
overcome this limitation, efforts have been
made to find alternative, efficient, non–donor-
dependent systems to generate platelets,
exploiting in vitro culture systems to
differentiate megakaryocytes from
hematological stem cells or induced
pluripotent stem cells.
There are 2 principal strategies used to
generate platelets ex vivo.Onemethod relies on
the collection of platelets from megakaryocytes
or in a bioreactor system. This method
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Dimerized P-selectin, which is expressed on the membrane of activated platelets and the endothelium, binds PSGL-1
on leukocytes to mediate adhesion and signaling, leading to inflammation. These pathways lead to proteolytic shedding
of P-selectin, releasing sP-selectin, a monomer. Circulating monomeric sP-selectin binds PSGL-1 less well and does
not induce leukocyte signaling, leading to inflammation.
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allows production of large amounts of platelets,
but these show weak responses to agonist
stimulation and a short half-life when infused
in immunodeficientmice.4 In a secondmethod,
in vitro–differentiated megakaryocytes are
infused and undergo platelet release in vivo
based on the theory that megakaryocytes shed
platelets in the lung.5 Two pools of human
platelets are detected in the circulation upon
infusion of in vitro–grown megakaryocytes.
One pool appears a few hours postinfusion and
shows comparable size, yield, half-life, and
function to donor-derived platelets. A second
pool consisting of platelet-like particles is
detected immediately upon infusion and differs
in size, yield, half-life, and function compared
with donor-derived platelets.6 Although in
vitro culture systems can be exploited to
generate megakaryocytes able to release
functional platelets in vivo, these systems also
generate damaged cells releasing platelet-like
particles. Furthermore, 1 limitation of the in
vitro–differentiation system is that only 10% to
30% of ex vivo–differentiated megakaryocytes
show the ability to generate platelets; thus,
the yield of in vivo releasable platelets remains
too low to be used clinically to substitute for
donor-derived platelets.7 One of the big
challenges to overcome is the identification
and definition of the maturation stage of
the megakaryocyte that is ready to release
platelets.
The interesting article by Sim et al
identifies specific markers useful in selecting
in vitro undamaged human megakaryocyte
populations that, when infused inmice, are able
to release fully functional platelets. These
megakaryocyte populations are characterized
by high granularity and CD42 expression.
Furthermore, the authors show that these
megakaryocyte populations preferentially
internalize factor V; endocytosed factor V can
be used as a marker to selectively enrich the
population of megakaryocytes primed for
platelet release. Because culture conditions
over time can damage cells inducing apoptosis
and shedding of surface receptors, Sim et al
show that pharmacological treatment of
differentiating cultures with apoptosis
inhibitors can be a useful tool to increase the
percentage of fully mature megakaryocytes,
thus resulting in increased platelet yield
in vivo (see figure).
One caveat of this approach is that the use of
an endocytosed protein, such as factor V, as
a marker of differentiation is cumbersome
to employ on an industrial scale for platelet
production for transfusions. Future studies
are required to identify new surface markers
more easily applicable in isolating such
megakaryocyte populations to efficiently
generate either in vitro or in vivo functional
platelets.
This study sheds new light on the
mechanisms of human megakaryopoiesis
and thrombopoiesis and provides a new
method that could potentially improve
platelet production for clinical use.
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Schematic showing the newly identified differentiation stages in human megakaryopoiesis. (A) Immature low granular
(LG) megakaryocytes (MKs) have low ploidy and few a granules. (B) These LG MKs mature in high granular (HG)/
CD42b1 MKs characterized by increased ploidy, RNA, and a granule content. (C) Mature HG/CD42b1 MKs internalize
factor V (FV) into their a granules and release FV-labeled platelets. The FV-labeled platelets are similar in size or larger
than human donor platelets. (D) Pharmacological inhibition of CD42b shedding from MKs does not prevent apoptosis or
improve MK functionality. (E) However, pharmacological inhibition of apoptosis increases the number of CD42b1/FV1
MKs that release functional platelets. The figure has been adapted from Figure 7 in the article by Sim et al that begins
on page 192.
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